Vigil Neuroscience(VIGL) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update - Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval pathway in ALSP - - Announced interim data from VG-3927 Phase 1 trial in healthy volunteers that support continued development as potential therapy for Alzheimer's disease - WATERTOWN, Mass., August 13, 2024 (G ...